Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Pilot Study to Explore the Feasibility of Navigator and Coach Support for Community Participation by Older People (ENGAGE)

19. September 2026 aktualisiert von: Bastiaan Van Grootven

A Randomised Pilot Study of Navigator and Coach Support for Participation in Community Activities to Promote Physical Activity and Social Contact in Persons Aged 65 Years and Older

Frailty is a multidimensional syndrome in which a person accumulates age-related deficits across life domains, increasingly including social components such as social isolation. An estimated 12% of the Swiss population aged 65+ is frail and a further 46% pre-frail; without prevention, about two thirds of pre-frail persons will become frail, with major consequences for disability, hospitalisation, mortality, quality of life and health costs. Meta-analyses identify physical activity as the most promising prevention strategy, yet structured mechanisms connecting older adults with existing community activities remain underdeveloped and fragmented. To close this implementation gap, the ENGAGE implementation project co-designed a community participation support pathway with local stakeholders: older adults with low physical and/or social activity are systematically identified during routine contacts, a values-based conversation clarifies what matters to the person, the person is matched and referred to existing community activities, and a navigator (a social work professional acting as link worker) provides behavioural, practical and emotional support for initial and continued participation. Because there are uncertainties in the delivery of the study and intervention, a pilot study with a pragmatic randomised trial design is implemented.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

45

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

65 Jahre und älter (Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age ≥65 years
  • Community-dwelling in Basel-Stadt/Basel-Landschaf
  • Low levels of physical activity and/or low levels of social activity or perceptions of social isolation
  • Sufficient German to understand the study information
  • Give written informed consent

Exclusion Criteria:

  • Residing in residential long-term care
  • Inability to move outside the home without another person's assistance (mobility aids and transport services are permitted)
  • Participation in a conflicting study
  • Severe cognitive impairment, severe psychiatric illness, communication barrier or sensory impairment precluding informed consent or meaningful engagement

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Versorgungsforschung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Standard of care

Participants remain free to receive usual care, professional advice, community information and community services that would normally be available outside the study.

Experimental: Navigation support

In intervention arm 1, patients are connected with a navigator. The navigator is a social worker trained to conduct a needs assessment and support an older person in finding and attending an appropriate community activities/services.

The navigator conducts a needs assessment and support an older person in finding and attending an appropriate community activities/services. They can offer a brief and limited set of behavioral change techniques (such as information about health consequences, goal setting, action planning, and discussing barriers) to support attendance and provide follow-up.

Experimental: Navigation and support support

In intervention arm 2, patients are connected with a navigator and a coach. Navigator support in this arm will be the same as for intervention arm 1, while the coaching will be provided by a trained member of the trial team. Coaching will follow-up on the initial navigation support, and will include a more intensive behavioural support.

The navigator conducts a needs assessment and support an older person in finding and attending an appropriate community activities/services. They can offer a brief and limited set of behavioral change techniques (such as information about health consequences, goal setting, action planning, and discussing barriers) to support attendance and provide follow-up.

Coaching will follow-up on the initial navigation support (e.g., needs elicitation, activity matching, goal setting, action planning), and will include a more intensive behavioural support. This will be based on motivational interviewing, which is used to conduct a live behavioural diangnosis using the COM-B model, and subsequent selection of one or more appropriate behavioural change techniques, individualised to the participant.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression decision to full trial
Zeitfenster: From enrollment until month 3

The primary endpoint for the pilot is the overall progression decision after the internal pilot, classified as: proceed to the full RCT without modifications; proceed with modifications; or stop.

From enrollment until month 3

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Feasibility of start-up procedures
Zeitfenster: From study enrolment until randomisation at around 2 weeks

The endpoint will be expressed as the number and type of problems identified per procedure domain (recruitment, consent, home-visit procedures, baseline assessment, data entry, randomisation, communication with study partners, and preparation for intervention initiation). Problems will be categorised as minor operational issue, major operational issue requiring procedure change, or critical issues requiring amendments to the ethics dossier.

From study enrolment until randomisation at around 2 weeks
Number of potential participants screened, recruited, randomised and retained
Zeitfenster: From enrollment until month 3

The endpoint will be expressed as the number and proportion of potential participants identified, screened, eligible, consented, randomised, and retained until the month 3 follow-up.

From enrollment until month 3
Reasons for refusal, discontinuation, withdrawal or loss to follow-up
Zeitfenster: From enrollment until month 3

The endpoint will be expressed as the number and proportion of reasons for non-participation, discontinuation of the allocated pathway, withdrawal from study procedures, withdrawal of consent, and loss to follow-up where available.

From enrollment until month 3
Completeness of full-trial outcome data
Zeitfenster: From enrollment until month 3

The endpoint will be expressed as the number and proportion of participants with complete data per instrument and timepoint for the primary and key secondary full trial endpoints.

From enrollment until month 3
Parameters informing the full-trial sample-size assumptions:
Zeitfenster: From enrollment until month 3

The endpoint will be expressed as the observed standard deviation of the Tilburg Frailty Indicator at month 3, the observed residual standard deviation, the correlation between baseline and month 3 scores, and case-load per Navigator.

From enrollment until month 3
Contamination between study arms
Zeitfenster: From enrollment until month 6

The endpoint will be expressed as the number and proportion of participants per arm with documented contamination, categorised by type and source, with a short qualitative summary.

From enrollment until month 6
Adoption of the ENGAGE Pathway: number and percentage of approached organisations and individual deliverers reaching each adoption Stage.
Zeitfenster: From enrolment until month 3

The endpoint will be expressed, per implementation region, as: 1) the number and proportion of approached organisations and individual deliverers progressing through each stage of adoption; and 2) the number and type of operational deliverers and case-finding routes. The endpoint will be measured using the ENGAGE Implementation Logbook.

From enrolment until month 3
Implementation-Strategy Fidelity: number and percentage of prespecified implementation strategies delivered as planned, partially delivered, or not delivered.
Zeitfenster: From enrolment until month 3

Implementation-strategy fidelity is defined as the degree to which the research team delivered the prespecified implementation strategies as specified, against each strategy's prespecified actor, action, dose and temporality. The endpoint will be expressed as: 1) the number and proportion of prespecified implementation strategies classified as delivered as planned, partially delivered, or not delivered; and 2) the reasons for partial or non-delivery. The endpoint will be measured using the ENGAGE Implementation Logbook.

From enrolment until month 3
Implementer experience and perceptions:
Zeitfenster: From enrollment until month 3

The endpoint will be expressed as a thematic summary and recommended adaptations for the full trial.

From enrollment until month 3
Delivered dose and participant responsiveness: number and percentage of participants achieving each engagement milestone, and number and duration of navigator and coaching contacts received.
Zeitfenster: From enrollment until month 3

Delivered dose is the number, mode, content and duration of navigator and coaching contacts provided to participants. Participant responsiveness is the degree to which participants engage with the support and the activities, covering enrolment in, first attendance at, and continued participation in community activities; discontinuation; and engagement with navigator and coaching contacts. The endpoint will be expressed, separately by study arm, as: 1) the number and proportion of participants achieving each engagement milestone; and 2) the number and duration (minutes) of navigator and coaching contacts received per participant. The endpoint will be measured using the ENGAGE Intervention Logbook.

From enrollment until month 3
Participant experience, perceived value and determinants of participation
Zeitfenster: From enrollment until month 3

The endpoint will be expressed as a thematic summary of participant experience.

From enrollment until month 3

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Mitarbeiter

Ermittler

  • Hauptermittler: Bastiaan Van Grootven, University of Basel - Public Health - Nursing Science

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Oktober 2026

Primärer Abschluss (Geschätzt)

30. September 2027

Studienabschluss (Geschätzt)

30. September 2028

Studienanmeldedaten

Zuerst eingereicht

12. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. September 2026

Zuerst gepostet (Tatsächlich)

23. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 2026-01725
  • 223834 (Andere Zuschuss-/Finanzierungsnummer: Swiss National Science Foundation)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

The endpoints in this pilot study concern feasibility indicators. The results in itself provide the full data. If a progression to the full trial is made, a separate registration with IPD will be made.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren